Category: Press Release

FierceMedTech Names Analytics 4 Life as One of its Fierce 15 MedTech Companies of 2017

RESEARCH TRIANGLE PARK, NC and TORONTO, ON, December 11, 2017 — Analytics 4 Life, a digital health company applying the power of artificial intelligence to develop solutions that improve existing care pathways, today announced that it has been named by FierceMedTech as one of 2017’s Fierce 15 medtech companies, designating it as one of the most promising private medtech companies in the industry.

Analytics 4 Life’s innovative technology combines artificial intelligence, cloud computing, and digital technologies to develop a proprietary approach to cardiac imaging, Phase Space Tomography™. The first application of this technology is CorVista™, a physician-directed diagnostic test that aims to assist in identifying the presence of coronary artery disease (CAD) without the use of radiation, cardiac stress, contrast agents, or patient fasting. CorVista is currently undergoing a clinical study at 13 sites in the U.S. to support algorithm development and regulatory filings. The ongoing Coronary Artery Disease Learning and Algorithm Development (CADLAD) clinical study, with more than 2,500 patients enrolled to date, will measure the performance of a machine-learned algorithm for CAD detection. Positive preliminary results from the company’s CADLAD study were presented in October of this year at the Transcatheter Cardiovascular Therapeutics (TCT) conference in Denver.

“Analytics 4 Life is honored to be recognized as one of the most innovative medtech companies selected for this year’s FierceMedTech Fierce 15,” said Don Crawford, Analytics 4 Life chief executive officer. “We’re proud to pioneer Phase Space Tomography, and are looking forward to working closely with the FDA to bring this game-changing technology to the millions of people affected by CAD.”

An internationally recognized daily report reaching a network of over 90,000 medtech industry professionals, FierceMedTech provides subscribers with an authoritative analysis of the day’s top stories. Every year FierceMedTech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

About FierceMedTech
FierceMedTech keeps biopharma executives, device developers, engineers, and researchers updated on the must-know news, trends and developments in medical devices and diagnostics. More than 90,000 top industry professionals rely on FierceMedTech for an insider briefing on the day’s top stories.

About Coronary Artery Disease
Coronary Artery Disease (CAD) is when the heart becomes weakened from a deficient supply of oxygenated blood due to a buildup of plaque in the coronary arteries, which can lead to blood clots, chest pain, and cardiac arrest. CAD affects approximately 15.5 million Americans and is the number one cause of death in the U.S.

About Analytics 4 Life
Analytics 4 Life is pioneering digital health using artificial intelligence to develop a completely new form of medical imaging. With an initial focus on coronary artery disease (CAD), Analytics 4 Life is advancing a novel, radiation-free, and exercise-free cardiac imaging technology aimed at improving existing care pathways. Analytics 4 Life is based in Toronto with U.S. headquarters in Research Triangle Park, NC. For more information, visit www.analytics4life.com.

Contacts

Analytics 4 Life
Jon Slebodnick
919-241-8736 x1013
info@analytics4life.com

W2Opure
Rachel St. Martin
646-894-5757
rstmartin@w2ogroup.com

FierceMedTech
Rachel St. Martin
202-824-5050
rebecca@fiercemarkets.com

SOURCE: PR Newswire

Analytics 4 Life to Present New Clinical Data on Novel Cardiac Imaging Technology Using Machine-Learned Algorithms at the Transcatheter Cardiovascular Therapeutics (TCT) 2017 Scientific Symposium

Initial Data from Ongoing Study Evaluates Diagnostic Performance in Obese, Elderly, and Female Patients

Dr. Thomas Stuckey to Lead Innovation Session Discussion on Non-invasive Detection of Coronary Artery Disease Using Resting Phase Signals

RESEARCH TRIANGLE PARK, NC and TORONTO, ON, October 30, 2017 — Analytics 4 Life, a digital health company applying the power of artificial intelligence to develop solutions that improve existing care pathways, today announced it will be presenting new clinical data on the Company’s ongoing Coronary Artery Disease Learning and Algorithm Development (CADLAD) study at the Transcatheter Cardiovascular Therapeutics (TCT) 2017 scientific symposium in Denver.

“We are encouraged by these initial results which suggest that our cardiac imaging technology has clinically significant utility in assessing coronary artery disease (CAD), without the need for radiation, exercise or pharmacologic stress,” said Don Crawford, CEO, Analytics 4 Life. “Conventional CAD detection pathways may be less accurate in specific populations, such as obese, elderly and female patients, but these early results show a promising potential for alternative technology.”

The CADLAD study is a two-stage clinical trial at 13 sites in the U.S. measuring the diagnostic performance of the company’s cardiac Phase Space Tomography Analysis (cPSTA) System in assessing cardiac health related to the presence of CAD. The cPSTA System, or CorVista™, is a non-invasive, physician-directed diagnostic test that uses a hand-held device to scan intrinsic signals from the body without radiation, contrast agents, or cardiac stress. The signal data is then transmitted to a secure, cloud-based repository for analysis, and a report is generated to help physicians assess the presence of CAD.

The ongoing study is designed to test the utility of cPSTA in a large population and other important subgroups. Enrollment into the study’s first stage, focused on product development, is complete with enrollment in the study’s second stage finishing before the end of this year. Results will be available early 2018 and will support the company’s U.S. FDA regulatory application.

Details of the two poster presentations and lecture at the TCT 2017 scientific symposium are as follows:

Title: Noninvasive Detection of Coronary Artery Disease Using Resting Phase Signals and Advanced Machine Learning
Presenter: Dr. Thomas Stuckey, Clinical Professor of Medicine, UNC School of Medicine, Cone Health Heart and Vascular Center Greensboro, NC
Session Title, Date and Time: Interventional Innovation I: Emerging Devices and Technological Concepts, Monday, October 30 at 8:35 a.m. MDT

Abstract Title: TCT 154: Gender Based Assessment of Coronary Artery Disease by Cardiac Phase Tomography Using Machine-Learned Algorithms
Presenter: Dr. Thomas Stuckey, Clinical Professor of Medicine, UNC School of Medicine, Cone Health Heart and Vascular Center Greensboro, NC
Session Title, Date and Time: Monday, October 30 at 10:42 a.m. MDT

Abstract Title: TCT 177: Assessing Coronary Artery Disease by Cardiac Phase Tomography Using Machine-Learned Algorithms in Obese and Elderly Subjects
Presenter: Dr. Thomas Stuckey, Clinical Professor of Medicine, UNC School of Medicine, Cone Health Heart and Vascular Center Greensboro, NC
Session Title, Date and Time: Monday, October 30 at 11:18 a.m. MDT

  • Coronary angiography results were paired with cPSTA data from 512 subjects to generate a machine-learned algorithm to assess for significant CAD
  • A separate verification cohort of 94 subjects was used to prospectively test the accuracy
  • Analyses focused on total verification population and on CADLAD by gender (male vs. female), age (> 65 vs. < 65 years of age), and obesity (BMI of > 30 vs. < 30)
  • Results suggest that the cPSTA System performs well overall across the verification population and respective subpopulations

About the Coronary Artery Disease Learning and Algorithm Development (CADLAD) Clinical Study
A two-stage investigational study at 13 sites in the U.S. is currently underway to support CorVista’s development and regulatory filings. The ongoing study, with more than 2,000 patients enrolled so far, will develop and measure the performance of a machine-learned algorithm for CAD detection.

About Coronary Artery Disease
Coronary Artery Disease (CAD) is when the heart becomes weakened from a deficient supply of oxygenated blood due to a buildup of plaque in the coronary arteries, which can lead to blood clots, chest pain, and cardiac arrest. CAD affects approximately 15.5 million Americans and is the number one cause of death in the U.S.

About CorVista
CorVista is designed to scan signals emitted by the body with a synchronous array of seven sensors on Analytics 4 Life’s proprietary collection device. After the signals are acquired, the signal package is instantaneously transmitted to the cloud where it is analyzed by a machine-learned algorithm to generate a unique image and a heart model indicating areas of potential heart disease associated with the presence of CAD. The results of the test are displayed on a secure physician web portal that, in combination with a patient’s medical history, risk factors, and symptoms, are used by the interpreting physician to recommend further treatment. CorVista is an investigational device limited by federal law to investigational use. CorVista is not available for commercial distribution.

About Analytics 4 Life
Analytics 4 Life is pioneering digital health using artificial intelligence to develop a completely new form of medical imaging. With an initial focus on coronary artery disease (CAD), Analytics 4 Life is advancing a novel, radiation-free, and exercise-free cardiac imaging technology aimed at improving existing care pathways. Analytics 4 Life is based in Toronto with U.S. headquarters in Research Triangle Park, NC. For more information, visit www.analytics4life.com.

Contacts

Analytics 4 Life
Jon Slebodnick
919-241-8736 x1013
info@analytics4life.com

Pure Communications
Katie Engleman
910-509-3977
katie@purecommunications.com

SOURCE: PR Newswire

Analytics 4 Life Raises $25 Million in Series B Financing to Advance its Artificial Intelligence-Backed Cardiac Imaging Technology

Funding will Advance Proprietary Imaging Technology Designed to Assess Coronary Artery Disease in a Revolutionary Way

Renowned Medical Device Expert Dr. Aaron Berez Joins Board of Directors

RESEARCH TRIANGLE PARK, NC and TORONTO, CANADA, September 27, 2017 — Analytics 4 Life, a digital health company applying the power of artificial intelligence to develop solutions that improve existing care pathways, today announced it has completed a $25 million Series B financing. This unique financing event was supported by an international syndicate of accredited investors, including physicians, healthcare professionals, and medical device experts. The Company’s novel cardiac imaging technology is under clinical investigation to help physicians assess the presence of coronary artery disease (CAD) using intrinsic signals scanned from the body without radiation, contrast agents, or cardiac stress.

“Heart disease is the leading cause of death globally, with 1 in 7 deaths in the U.S. attributed to CAD. We are thankful for the continued support from passionate investors who have made it possible for us to revolutionize the way that CAD is diagnosed,” said Don Crawford, CEO of Analytics 4 Life. “Securing this oversubscribed financing fuels our rapid growth to advance development of our diagnostic tool and gives us the resources we need to deliver this game-changing technology to patients and physicians.”

Current diagnostic methods for CAD are costly, risky, and time-consuming. Analytics 4 Life seeks to address these challenges with its novel method of cardiac imaging. The Company’s state-of-the-art technology represents a new approach to cardiac imaging based on advanced disciplines of mathematics and physics combined with the power of cloud computing and artificial intelligence. The first application of this technology is CorVista™, a non-invasive, physician-directed diagnostic test that aims to identify the presence of CAD without radiation or cardiac stress.

CorVista is designed to scan signals naturally emitted by the body with a synchronous array of seven sensors on Analytics 4 Life’s proprietary collection device. After the signals are acquired, the signal package is instantaneously transmitted to the cloud where it is analyzed by a machine-learned algorithm to generate a unique image and a heart model indicating areas of potential heart disease associated with the presence of CAD. The results of the test are displayed on a secure physician web portal that, in combination with a patient’s medical history, risk factors, and symptoms, are used by the interpreting physician to recommend further treatment.

Coronary Artery Disease Learning and Algorithm Development (CADLAD) Clinical Study

A two-stage clinical trial at 13 sites in the U.S. is currently underway to support CorVista’s development and regulatory filings. The ongoing study, with more than 2,000 patients enrolled so far, will measure the performance of a machine-learned algorithm for CAD detection to gold-standard cardiac catheterization results.

Preliminary results will be presented next month at the Transcatheter Cardiovascular Therapeutics (TCT) conference in Denver. Assuming a positive FDA review, the Company anticipates having CorVista available in the U.S. next year.

Dr. Aaron Berez Appointed to Board of Directors

Also today, Analytics 4 Life announced the appointment of Aaron Berez, M.D., to its board of directors. Dr. Berez is the founder and CEO of Alembic LLC, an early-stage medical device company, and has been leading and advising medical device companies for more than 20 years.

“Today marks an important milestone for the Company, but also for the 15.5 million Americans living with coronary heart disease,” said Dr. Berez. “I’m excited and honored to join Analytics 4 Life’s Board of esteemed experts as we chart a path toward bringing this potentially transformative way to diagnose cardiovascular disease to patients and physicians.”

Previously, Dr. Berez co-founded and served as CEO of Chestnut Medical, acquired by Ev3 (now Medtronic) in 2009, where he led the development of the Pipeline Embolization Device for the treatment of complex intracranial aneurysms. Dr. Berez is currently an investor, advisor, and director to privately held medical device companies focused on capital-efficient medical device development.

About Coronary Artery Disease

Coronary Artery Disease (CAD) is when the heart becomes weakened from a deficient supply of oxygenated blood due to a buildup of plaque in the coronary arteries, which can lead to blood clots, chest pain, and cardiac arrest. CAD affects approximately 15.5 million Americans and is the number one cause of death in the U.S.

About Analytics 4 Life

Analytics 4 Life is pioneering digital health using artificial intelligence to develop a completely new form of medical imaging. With an initial focus on coronary artery disease (CAD), Analytics 4 Life is advancing a novel, radiation-free, and exercise-free cardiac imaging technology aimed at improving existing care pathways. Analytics 4 Life is based in Toronto with U.S. headquarters in Research Triangle Park, NC. For more information, visit www.analytics4life.com.

Contacts

Analytics 4 Life
Jon Slebodnick
919-241-8736 x1013
jon@analytics4life.com

Pure Communications, Inc.
Katie Engleman
910-509-3977
katie@purecommunications.com

SOURCE: PR Newswire

A4L Expands into JLABS @ Toronto

TORONTO, ON – Jan. 16, 2017 – Today, Analytics 4 Life (A4L), a machine intelligence company developing noninvasive, cost-effective medical devices, announced its expansion into JLABS @ Toronto, one of Johnson & Johnson Innovation’s life science incubators. As a resident in the space, A4L has access to a rich ecosystem of cardiovascular medical device development and commercialization expertise.

JLABS @ Toronto is a life science innovation center that provides a flexible environment for start-up companies pursuing new technologies and research platforms to advance medical care. Through a “no strings attached” model, Johnson & Johnson Innovation does not take an equity stake in the companies occupying JLABS and the companies are free to develop products—either on their own, or by initiating a separate external partnership with Johnson & Johnson Innovation or any other company.

“This is a unique opportunity for A4L to leverage the mentorship of the organization and the JLABS infrastructure that will be beneficial to developing machine-learned solutions,” says Ian Shadforth, Chief Technology Officer at A4L. “We are very excited to locate our medical device product development team here as we continue rapid advancement of our initial product, CorVista™, through clinical trials.” Last year, A4L announced its participation in the IBM Innovation Space, where its Agilytics™ machine learning platform development team is housed.

In May 2016, A4L launched its multi-center Coronary Artery Disease Learning and Algorithm Development (CADLAD) clinical study that will enroll up to 2,500 subjects from up to 25 medical centers within the United States. “This is a two-stage study where we will first develop our machine-learned algorithm for detecting CAD using paired physiologic signals and clinical outcomes data. Then, we will subsequently test that algorithm in a prospective, blinded, non-randomized, paired comparison trial,” says Dr. Williams Sanders, Chief Medical Officer, “In March, we will be presenting preliminary results of our work at the American College of Cardiology (ACC) conference.”

About A4L
Analytics 4 Life (A4L) has developed a proprietary signal processing and machine intelligence platform, Agilytics™, to produce machine-learned solutions for the purposes of detecting disease. Agilytics™ works by mathematically deciphering critical patterns and relationships from billions of captured data points paired with clinical results. By applying this platform to cardiac Phase Space Tomography Analysis (cPSTA) data and paired coronary angiography results, A4L has developed CorVista™, its initial product focused on coronary artery disease (CAD). CorVista™ aims to noninvasively assess the presence of significant CAD in a single office visit without radiation, exercise, or pharmacological stressors using physiologic signals naturally emitted by the body. Beyond CAD, A4L has begun applying Agilytics™ to expand CorVista™ into other cardiac conditions as well as to engineer new products to address disease states in neurology and oncology.

Investigational Device – CorVista™ is currently under clinical investigation and is not available for commercial distribution.

MEDIA CONTACT:
Jon Slebodnick
Marketing & Business Development
jon@analytics4life.com

SOURCE: PR Newswire

A4L Announces IBM Innovation Space Participation

TORONTO, ON – Sep. 22, 2016 – Yesterday at a gathering of IBM executives and Ontario government officials, Analytics 4 Life (A4L), a Toronto-based eHealth company, announced its participation in the new and first IBM Innovation Space. Earlier this year, the Ontario government partnering with the Ontario Centres of Excellence (OCE) and IBM committed $54 million to support the creation of innovation hubs across Ontario to help small- and medium-sized businesses fast-track the introduction of new technologies and global expansion.

As a flagship company in the program, A4L was one of the first ventures to occupy space in the Toronto-based technology centre. The new office space provides access to technical resources, including IBM Cloud, IBM Watson cognitive business technology, IBM SoftLayer, and the IBM Bluemix cloud development platform. This collaboration equips A4L with secure and scalable cloud infrastructure to support its machine intelligence platform, Agilytics™.

Founded in Kingston, ON, privately-funded A4L now has offices in Toronto and the Research Triangle Park in North Carolina. “A few years ago, a small group of scientists at A4L realized that by applying machine learning to the signals naturally generated by the body, they could identify disease states,” says Ian Shadforth, A4L’s Chief Technology Officer. “Now we are building cloud-based medical device products that leverage a world-class suite of IBM cloud services to rapidly achieve our product development goals.”

In May 2016, the company launched its multi-center Coronary Artery Disease Learning and Algorithm Development (CADLAD) clinical study that will enroll up to 2,500 subjects from up to 25 medical centers within the United States. Chief Medical Officer, Dr. William Sanders, says, “A4L is currently testing a system that safely records patient signals and wirelessly transmits these files to secure cloud storage that allows powerful computer analytics to access and analyze billions of data points in real time.” He added, “CorVista™ is an investigational device and has not been approved for commercial distribution.”

The IBM Innovation Space was developed through Ontario’s Jobs and Prosperity Fund, which is expected to create up to 2,600 jobs and generate $410 million in follow-on investment.

About A4L
Analytics 4 Life (A4L) is a Toronto-based eHealth company using advanced phase signal processing techniques and machine learning for the purposes of identifying and assessing disease with its initial CorVista™ product focused on coronary artery disease (CAD). Beyond CAD, A4L has started to apply its machine intelligence platform, Agilytics™, to address other disease states in cardiology as well as neurology and oncology.

MEDIA CONTACT:
Jon Slebodnick
Marketing & Business Development
jon@analytics4life.com

SOURCE: PR Newswire

A4L Announces Research Award from SOSCIP and OCE

TORONTO, ON – Sep. 14, 2016 – Today, Analytics 4 Life (A4L), a Toronto-based eHealth company, announced its second project award by Southern Ontario Smart Computing Innovation Platform (SOSCIP) and Ontario Centres of Excellence (OCE). The focus of the new project is to create a proprietary machine learning computational algorithm that can analyze physiologic signals and identify patterns related to heart disease.

SOSCIP is a research and development consortium that pairs academic and industry researchers with advanced computing tools to fuel innovation leadership in Canada. SOSCIP and OCE granted access and funding for A4L’s first research project that demonstrated the ability to predict hidden heart disease in controlled animal lab experiments. The results of A4L’s initial research project in collaboration with Dr. Terrence Ozolins from Queen’s University have been submitted for publication and is currently pending.

This second SOSCIP and OCE supported project will process billions of data points acquired from A4L’s ongoing US-based multicenter clinical study that is enrolling up to 2,500 subjects at as many as 25 sites. “Together, A4L and SOSCIP are exploring the use of advanced tools, such as IBM’s BlueGene/Q supercomputing and the new Quantum Experience, to enable our scientists to investigate larger search spaces and find optimal solutions efficiently,” says Sunny Gupta, A4L’s Founder and Chief Scientific Officer.

Privately-held Analytics for Life Inc. was founded in 2012 as an information technology company and currently has offices in Toronto and the Research Triangle Park in North Carolina. Don Crawford, A4L’s CEO, says, “The support of SOSCIP and OCE has helped the company’s Toronto-based technology development center rapidly expand to support the company’s aggressive product development goals.”

About A4L
Analytics 4 Life (A4L) is a Toronto-based eHealth company using advanced phase signal processing techniques for the purposes of identifying and assessing disease with an initial focus on coronary artery disease (CAD). Beyond coronary artery disease, A4L has started to apply its platform technology to address other disease states in cardiology as well as neurology and oncology.

About SOSCIP
Southern Ontario Smart Computing Innovation Platform (SOSCIP) is a research and development consortium that pairs academic and industry researchers with advanced computing tools to fuel innovation leadership in Canada. The consortium includes 15 universities as well as the Ontario Centres of Excellence and IBM Canada Research and Development Centre.

About OCE
Ontario Centres of Excellence (OCE) drives the development of Ontario’s economy by helping create new jobs, products, services, technologies and businesses. OCE’s efforts are focused on sectors of the economy with the greatest potential to drive Ontario’s future prosperity and global competitiveness: energy and environment (including water); advanced manufacturing; advanced health technologies; and information, communications technologies and digital media.

MEDIA CONTACT:
Jon Slebodnick
Marketing & Business Development
jon@analytics4life.com

SOURCE: PR Newswire

A4L Appoints William E. Sanders, Jr. MD MBA Chief Medical Officer And Nick Leb Chief Financial Officer

TORONTO, Jan. 12, 2016 /PRNewswire/ — A4L (Analytics 4 Life), a medical information technology company that uses advanced signal processing techniques for the purposes of detecting and assessing disease, today announced the appointment of William E. (Gene) Sanders, Jr. MD MBA as Chief Medical Officer and Nick Leb as Chief Financial Officer.

“Gene and Nick are seasoned executives with substantial healthcare experience who will provide sound clinical, financial and strategic leadership as we continue to grow and build our management team,” commented Don Crawford, President and CEO. “Gene will play an immediate key role in clinical site selection and investigator relations as we continue to prepare for our clinical trials in the coming months. Nick will establish the infrastructure and corporate governance required to sustain and expand our organization.  I am excited to welcome both to the A4L team.”

Dr. Sanders is a cardiologist with 30 years of medical experience specializing in Clinical Cardiac Electrophysiology. Most recently Dr. Sanders served as FDA Medical Officer of the Cardiac Electrophysiology Device Branch within the Cardiovascular Devices Division. Previously, Dr. Sanders was an Associate Professor of Medicine and Pathology atUniversity of North Carolina at Chapel Hill, where he spent 15 years as the Director of Clinical Cardiac Electrophysiology and Pacing and Associate Director of Cardiovascular Diagnostic and Interventional Laboratories. He has been directly involved in the success of multiple start-up medical device companies, acting as a consultant and board member.

Nick Leb is a proven financial executive with over 25 years of experience in public accounting, finance, treasury and investor relations in both publicly traded and privately held corporations. Nick joins A4L after serving as CFO for Sapheon Inc., which was recently acquired by Medtronic, where he was responsible for all accounting, finance and treasury functions for both the US parent corporation and the Dutch subsidiary. Previously, he served as CFO for KBI Biopharmaceuticals and Vice President of Finance for Accentia BioPharmaceuticals, TEAMM Pharmaceuticals, Brightstone Pharma and Global Surgical Corporation. He previously served as Corporate Controller for KV Pharmaceuticals and as a Director for Vyrix Pharmaceuticals, Inc. and BioVest International, Inc.

MEDIA CONTACT:
Jon Slebodnick
Marketing & Business Development
jon@analytics4life.com

SOURCE: PR Newswire

A4L Raises C$10m Series A Financing And Appoints Don Crawford President And Chief Executive Officer

TORONTO, Jan. 6, 2016 /PRNewswire/ — A4L (Analytics 4 Life), a medical information technology company that uses advanced signal processing techniques for the purposes of detecting and assessing disease, today announced it has raised C$10 million in Series A financing by private accredited investors in an oversubscribed round. Additionally, the company announced the appointment of Don Crawford as President and Chief Executive Officer.

A4L has developed a novel technology that utilizes machine learning applied to data sets of patient physiologic signals and clinical outcomes information to detect and assess specific diseases. The goal is to provide rapid and accurate detection of disease states, thereby offering worldwide healthcare markets with cost-effective, efficient, and safe solutions. A4L has conducted initial in vivo laboratory research to analyze and manipulate two billion data points, which was supported by Southern Ontario Smart Computing Innovations Platform and the Ontario Centers of Excellence. Early results demonstrate that a machine learned algorithm is able to detect the presence of heart disease.

The C$10 million funding round will allow A4L to move forward with patient enrollment and clinical testing of its novel product in cardiac disease, the first application. “Additionally, we are building a world class management team to navigate and to meet the demands of the highly regulated healthcare industry,” says Don Crawford. “We have engaged Greg Davis of the Medcelerate Consulting Group based in Chapel Hill, North Carolina to manage operations and lead team recruiting.”

Mr. Crawford has an extensive history in the medical device field spanning more than 30 years, primarily focused on Cardiac Rhythm Management (CRM). His most recent executive management role as CEO and Founder of Sapheon, Inc. resulted in a successful exit to Covidien plc in 2014. Sapheon was subsequently acquired by Medtronic plc as part of its acquisition of Covidien, resulting in an exit value of up to $238 million paid to Sapheon investors and shareholders.

A4L’s headquarters and technology development are located in Toronto, Ontario where the majority of the software development occurs. A4L opened its U.S. subsidiary in the Research Triangle Park in North Carolina in early 2015, where company operations and hardware development are located. Mr. Crawford expects U.S. based clinical trials to start in the spring of 2016 to support FDA regulatory requirements.

MEDIA CONTACT:
Jon Slebodnick
Marketing & Business Development
jon@analytics4life.com

SOURCE: PR Newswire